NYSE · Biotechnology · USD
Veradermics, Incorporated (MANE) Stock Analysis
Veradermics, Incorporated (MANE) is a Biotechnology stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MANE Key Statistics
As of Oct 21, 2026Trading
- Open
- $127.50
- Previous Close
- $127.11
- Day's Range
- 127.78–139.12
- 52-Week Range
- 32.00–139.12
- Volume
- 706.80K
Valuation
- Market Cap
- $5.71B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.24
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$70.00M
- Shares Outstanding
- 41.78M
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 797.73K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
Veradermics, Incorporated (MANE) has a market capitalization of $5.71B.
In fiscal 2025, MANE reported revenue of $0.00.
MANE Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$70.00M | — |
| 2024 | $0.00 | −$26.49M | — |
| 2023 | $0.00 | −$16.49M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$71.56M | −$70.00M | — |
| 2024 | $0.00 | — | −$26.38M | −$26.49M | — |
| 2023 | $0.00 | — | −$17.32M | −$16.49M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Veradermics’ stock up on male hair loss trial success
clinicaltrialsarena.comVeradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment
TIKRVeradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
MarketBeatVeradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript
SeekingAlphaVeradermics stock surges as hair loss drug meets Phase 3 goals
YahooCould This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
Benzinga
All 20 articles ↓Show fewer ↑
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
BioPharma DiveVeradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
YahooSilence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
BenzingaCantor Fitzgerald Reiterates Overweight on Veradermicsto Overweight
BenzingaNeedham Maintains Buy on Veradermics, Raises Price Target to $172
BenzingaVeradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile
BenzingaVeradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
YahooVeradermics: The Momentum Is Building, But Know This Before H2 2026 Readouts
SeekingAlphaVeradermics: Buy Before The Catalysts
SeekingAlphaBaldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
YahooVeradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
SeekingAlphaVeradermics to Present at Upcoming September Investor Conferences
YahooVeradermics (MANE) Stock Looks Overvalued After Its 161% Rally
YahooIs Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B